OR WAIT null SECS
© 2022 MJH Life Sciences and Consultant Live. All rights reserved.
May 18, 2022
The first controlled trial of the combination therapy shows its benefit in 6-week depressive symptom improvement versus lone bupropion.
A South Korea in-hospital assessment found that approximately half of all ordered CDI tests did not meet recommendation standards.
May 17, 2022
Developing research into the specific alterations of dysbiosis and diseases like arthritis suggest possibly novel pathways to therapy development.
New data suggest prediction of SARS-CoV-2 and bacterial co-infection or superinfection could be provided for hospitalized patients.